title: Time-lag performance of radiofrequency ablation after percutaneous ethanol injection for the treatment of hepatocellular carcinoma.
abstract: We have previously reported that the combination therapy of percutaneous ethanol injection and radiofrequency ablation (PEI-RFA) was more effective than RFA alone to induce wider coagulated necrosis for the treatment of hepatocellular carcinoma (HCC). In the present study, the effect of time-lag performance of RFA after PEI was evaluated under the same ablation condition as PEI-RFA by analyzing the volume of coagulated necrosis, the energy requirement for ablation and the amount of ethanol injected into HCC. The comparative study between time-lag PEI-RFA and no time-lag PEI-RFA showed that the total energy requirement and the energy requirement per unit volume for whole and marginal coagulated necrosis were significantly smaller in the time-lag group than in the no time-lag PEI-RFA group. In time-lag PEI-RFA, the volume of coagulated necrosis induced positively correlated with the amount of ethanol injected into HCC as previously observed in PEI-RFA treatment. These results suggest that time-lag PEI-RFA can induce comparable coagulated necrosis with a smaller energy requirement than no time-lag PEI-RFA, and that time-lag PEI-RFA is likely to be less invasive than no time-lag PEI-RFA for inducing comparable coagulated necrosis. Thus, time-lag performance of RFA after PEI may make RFA treatment more effective and less invasive for the treatment of patients with HCC.
authors.affiliation: Third Department of Internal Medicine, Kagawa University School of Medicine, Kita-gun, Kagawa 761-0793, Japan.
authors.forename: Kazutaka
authors.initials: K
authors.lastname: Kurokohchi
authors.forename: Tsutomu
authors.initials: T
authors.lastname: Masaki
authors.forename: Seishiro
authors.initials: S
authors.lastname: Watanabe
authors.forename: Seiji
authors.initials: S
authors.lastname: Nakai
authors.forename: Akihiro
authors.initials: A
authors.lastname: Deguchi
authors.forename: Asahiro
authors.initials: A
authors.lastname: Morishita
authors.forename: Hirohito
authors.initials: H
authors.lastname: Yoneyama
authors.forename: Tomohiro
authors.initials: T
authors.lastname: Ohgi
authors.forename: Masahiro
authors.initials: M
authors.lastname: Ono
authors.forename: Akira
authors.initials: A
authors.lastname: Yoshitake
authors.forename: Takeshi
authors.initials: T
authors.lastname: Kako
authors.forename: Naoko
authors.initials: N
authors.lastname: Ohmachi
authors.forename: Takaaki
authors.initials: T
authors.lastname: Kiuchi
authors.forename: Tsuyoshi
authors.initials: T
authors.lastname: Maeta
authors.forename: Mitsuo
authors.initials: M
authors.lastname: Yoshida
authors.forename: Yoshihiro
authors.initials: Y
authors.lastname: Mori
authors.forename: Fumikazu
authors.initials: F
authors.lastname: Kohi
authors.forename: Shigeki
authors.initials: S
authors.lastname: Kuriyama
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D000891:Anti-Infective Agents, Local / Q000008:administration & dosage / Q000627:therapeutic use; D006528:Carcinoma, Hepatocellular / Q000628:therapy*; D017115:Catheter Ablation / Q000379:methods*; D003131:Combined Modality Therapy; D004305:Dose-Response Relationship, Drug; D000431:Ethanol / Q000008:administration & dosage / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D015552:Injections, Intralesional; D008113:Liver Neoplasms / Q000628:therapy*; D008297:Male; D008875:Middle Aged; D015203:Reproducibility of Results; D016896:Treatment Outcome
chemical_list: D000891:Anti-Infective Agents, Local; D000431:Ethanol